Eyenovia Reports Fourth Quarter 2022 Financial Results and P

30.03.2023 - Announced FDA acceptance of Mydcombi New Drug Application (NDA) and PDUFA action date of May 8, 2023 Announced positive results from Microline Phase 3 program as a potential treatment for presbyopia and received feedback from the FDA outlining a ...

Related Keywords

Hong Kong , South Korea , Canada , China , United States , Taiwan , Formosa , Americans , Michael Rowe , Norbert Lowe , Eric Ribner , John Gandolfo , Eyenovia Optejet , Lifesci Advisors , Eyenovia Inc , Exchange Commission , Drug Administration , Lomb Inc , Formosa Pharmaceuticals , Nasdaq , Recent Business , Prescription Drug User Fee Act , Microline Phase , Redwood City , Arctic Vision , Chief Executive Officer , Full Year , Greater China , Microdose Array Print , Eyenovia Corporate Information , Investor Contact , Sci Advisors , Media Contact , Stockholder Equity , Three Months , Loss Per Share , Average Number ,